Electrophysiologic parameters to predict clinical recurrence of ventricular tachycardia in patients under electrophysiologic study-guided effective pharmacological therapy

Japanese Circulation Journal

Volumn 63, Issue 9, 1999, Pages 674-680

  Niwano, Shinichi ^a   Yamaura, Masayuki ^b   Yoshizawa, Naoto ^a   Moriguchi, Masahiko ^a   Kitano, Yoshikazu ^a   Aizawa, Yoshifusa ^b   Izumi, Tohru ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

Author keywords

Antiarrhythmic drugs; Electrophysiologic study; Ventricular tachycardia

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; APRINDINE; CIBENZOLINE; DISOPYRAMIDE; FLECAINIDE; ISOPRENALINE; MEXILETINE; PROCAINAMIDE; PROPAFENONE; SOTALOL; VERAPAMIL;

ADOLESCENT; ADULT; AGED; ARTICLE; DRUG EFFICACY; ELECTROPHYSIOLOGY; FEMALE; HEART MUSCLE REFRACTORY PERIOD; HEART VENTRICLE TACHYCARDIA; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PROGNOSIS; QRS COMPLEX; RECURRENCE RISK; RECURRENT DISEASE;

ADOLESCENT; ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISOPROTERENOL; MALE; MIDDLE AGED; PACEMAKER, ARTIFICIAL; PROGNOSIS; RECURRENCE; TACHYCARDIA, VENTRICULAR;

EID: 0348202998     PISSN: 00471828     EISSN: None     Source Type: Journal    
DOI: 10.1253/jcj.63.674     Document Type: Article

References (28)

1. Graboys TB, Lown B, Podrid P, DeSilva R: Long-tenn survival of patients with malignant ventricular arrhythmia treated with antiarrhythmic drugs. Am J Cardiol 1982; 50: 437-443
2. Hohnloser SH, Raeder EA, Podrid PJ, Graboys TB, Lown B: Predictors of antiarrhythmic drug efficacy in patients with malignant ventricular tachyarrhythmias. Am Heart J 1987; 114: 1-7
3. Fisher JD, Cohen HL, Mehra R, Altschuler H, Escher DJW, Furman S: Cardiac pacing and pacemakers. II. Serial electrophysiologic-pharmacologic testing for control of reentrant tachyarrhythmias. Am Heart J 1977; 93: 658-666
4. Horowitz LN, Josephson ME, Farshidi A, Spielman SR, Michelson EL, Greenspan AM: Recurrent sustained ventricular tachycardia. 3. Role of the electrophysiologic study in selection of antiarrhythmic regimens. Circulation 1978; 58: 986-997
5. Mason JW, Winkle RA: Electrode-catheter arrhythmia induction in the selection and assessment of antiarrhythmic drug therapy for recurrent ventricular tachycardia. Circulation 1978; 58: 971-985
6. Josephson ME, Horowitz LN: Electrophysiologic approach to therapy of recurrent sustained ventricular tachycardia. Am J Cardiol 1979; 43: 631-642
7. Horowitz LN, Spielman SR, Greenspan AM, Josephson ME: Role of programmed stimulation in assessing vulnerability to ventricular arrhythmias. Am Heart J 1982; 103: 604-610
8. Swedlow CD, Winkle RA, Mason JW: Determinants of survival in patients with ventricular tachyarrhythmias. N Engl J Med 1983; 308: 1436-1442
9. Waller TJ, Kay HR, Spielman SR, Kutalek SP, Greenspan AM, Horowitz LN: Reduction in sudden death and total mortality by antiarrhythmic therapy evaluated by electrophysiologic drug testing: criteria of efficacy in patients with sustained ventricular tachyarrhythmia. J Am Coll Cardiol 1987; 10: 83-89
10. Mitchell LB, Duff HJ, Manyari DE, Wyse DG: A randomized clinical trial of the noninvasive and invasive approaches to drug therapy of ventricular tachycardia. N Engl J Med 1987; 317: 1681-1687
11. Mitchell LB, Duff HJ, Gillis AM, Ramadan D, Wyse DG: A randomized clinical trial of the non-invasive and invasive approaches to drug therapy for ventricular tachycardia: long-term follow-up of the Calgary trial. Prog Cardiovasc Dis 1996; 38: 377-384
12. The ESVEM investigators: The ESVEM Trial: Electrophysiologic Study Versus Electrocardiographic Monitoring for selection of antiarrhythmic therapy of ventricular tachyarrhythmias. Circulation 1989; 79: 1354-1360
13. Naccarelli GV, Prystowsky EN, Jackman WM, Heger JJ, Rahilly GT, Zipes DP: Role of electrophysiologic testing in managing patients who have ventricular tachycardia unrelated to coronary artery disease. Am J Cardiol 1982; 50: 165-171
14. Geibel A, Brugada P, Zehender M, Stevenson W, Waldecker B, Wellens HJJ: Value of programmed electrical stimulation using a standardized ventricular stimulation protocol in hypertrophic cardiomyopathy. Am J Cardiol 1987; 60: 738-739
15. Niwano S, Furushima H, Taneda K, Abe A, Ohira K, Aizawa Y: The usefulness of Holter monitoring in selecting pharmacological therapy for patients with sustained monomorphic ventricular tachycardia: Studies in patients in whom no effective pharmacologic therapy could be determined by electrophysiologic study. Jpn Circ J 1998; 62: in press.
16. Aizawa Y, Murata M, Satoh M, Aizawa M, Suzuki K, Kato H, et al: Five cases of arrhythmogenic left ventricular aneurysm unrelated to coronary occlusion. Jpn Circ J 1986; 50: 45-55
17. Niwano S, Aizawa Y, Satoh M, Chinushi M, Shibata A: Low energy electrical ablation for sustained ventricular tachycardia. Am Heart J 1991; 119: 81-88
18. Aizawa Y, Chinushi M, Naitoh N, Kusano Y, Kitazawa H, Takahashi K, et al: Catheter ablation with radiofrequency current of ventricular tachycardia originating from the right ventricle. Am Heart J 1993; 125: 1269-1275
19. Winkle RA, Mead RH, Ruder MA, Gaudiani VA, Smith NA, Buch WS, et al: Long-term outcome with the automatic implantable cardioverter-defibrillator. J Am Coll Cardiol 1989; 13: 1353-1361
20. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al: Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia: Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335: 1933-1940
21. Zipes DP, Roberts D, Pacemaker-Cardioverter-Defibrillator Investigators: Results of the international study of the implantable pacemaker cardioverter-defibrillator: A comparison of epicardial and endocardial lead system. Circulation 1995; 92: 59-65
22. Mirowski M, Reid PR, Mower MM, Watkins L, Gott VL, Schauble JF, et al: Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med 1980; 303: 322-324
23. The AVID Investigators: Antiarrhythmics versus implantable defibrillators (AVID): rationale, design, and methods. Am J Cardiol 1995; 75: 470-475
24. Dreifus LS, Fisch C, Griffin JC, Gillette PC, Mason JW, Parsonnet V: Guidelines for implantation of cardiac pacemakers and antiarrhythmic devices: A report of the ACC/AHA task force on assessment of diagnostic and therapeutic cardiovascular procedures (Committee on pacemaker implantation). Circulation 1991; 84: 455-467
25. Lehmann MH, Saksena S: Implantation of cardioverter-defibrillators in cardiovascular practice: report of the Policy Conference of the North American Society of Pacing and Electrophysiology (NASPE Policy Conference Committee). PACE 1991; 14: 967-969
26. Swedlow CD, Winkle RA, Mason JW: Prognostic significance of the number of induced ventricular complexes during assessment of therapy for ventricular arrhythmias. Circulation 1983; 68: 400-405
27. Reiffel JA, Reiter MJ, Freedman RH: Influence of Holter monitor and electrophysiologic study methods and efficacy criteria on the outcome of patients with ventricular tachycardia and ventricular fibrillation in the ESVEM trial. Prog Cardiovasc Dis 1996; 38: 359-370
28. Mitchell LB, Sheldon RS, Gillis AM, Connolly SJ, Duff HJ, Gardner MJ, et al: Definition of predicted effective antiarrhythmic drug therapy for ventricular tachyarrhythmias by the electrophysiologic study approach: randomized comparison of patient response criteria. J Am Coll Cardiol 1997; 30: 1346-1353